Literature DB >> 8615611

Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.

M Volm1, R Koomägi, J Mattern.   

Abstract

It has been shown that hypoxia can induce resistance to a number of antineoplastic agents. Since vessel density may be considered as an indirect measure of the oxygenation of tumours, in this study we analysed the relationship between tumour vascularity or vascular endothelial growth factor (VEGF) expression and drug resistance. Tumour specimens of 152 non-small cell lung carcinomas (NSCLC) of previously untreated patients were analysed for microvessel density by staining with factor VIII (von Willebrand factor) antibody and for expression of vascular endothelial growth factor (VEGF) using an anti-VEGF-antibody. Both proteins were determined by immunohistochemistry and the expression was compared with the resistance to doxorubicin measured in vitro. Microvessel density was significantly reduced in resistant tumours when compared with sensitive tumours. Of the 98 tumours with low microvessel density 83 (85%) were resistant; whereas of the 54 tumours with high microvessel density only 34 (63%) were resistant (p = 0.004). Expression of VEGF was significantly lower in resistant than in sensitive lung carcinomas. Of the 102 tumors with low expression of VEGF, 87 (85%) were resistant; whereas of the 50 tumors with high expression only 30 (60%) were resistant (p = 0.0009). Corresponding results were obtained when the analysis was restricted to squamous cell lung carcinomas or adenocarcinomas of the lung. Analysis of microvessel density or VEGF expression and clinical data (stage, histology, metastasis) revealed no significant interrelationships. These data show clearly that poor microvessel density (vascularisation) and reduced expression of VEGF are linked with resistance to doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615611

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma.

Authors:  Xiao-Nan Sun; Wei-Guo Cao; Xin Wang; Qi Wang; Ben-Xing Gu; Qi-Chu Yang; Jian-Bin Hu; Hai Liu; Shu Zheng
Journal:  Tumour Biol       Date:  2011-08-19

2.  Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions.

Authors:  D R Thickett; L Armstrong; A B Millar
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

3.  Correlation of P-glycoprotein expression with poor vascularization in human gallbladder carcinomas.

Authors:  Yu Tian; Li-Li Zhu; Ren-Xuan Guo; Chui-Feng Fan
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

4.  Role of oxygenation and vascularization in drug resistance.

Authors:  J Mattern; M Volm
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

5.  Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.

Authors:  K J O'Byrne; M I Koukourakis; A Giatromanolaki; G Cox; H Turley; W P Steward; K Gatter; A L Harris
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

6.  Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.

Authors:  Doan Chinh Chung; Le Thanh Long; Hoang Nghia Son; Le Tri Bao; Do Minh Si; Le Van Dong
Journal:  Cell J       Date:  2015-07-11       Impact factor: 2.479

7.  Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas.

Authors:  G Fontanini; L Boldrini; S Chinè; F Pisaturo; F Basolo; A Calcinai; M Lucchi; A Mussi; C A Angeletti; G Bevilacqua
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.